Rituximab

Drugs

Volumn 58, Issue 1, 1999, Pages 79-88

  Onrust, Susan V ^a   Lamb, Harriet M ^a   Barman Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; MONOCLONAL ANTIBODY; PARACETAMOL; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; B LYMPHOCYTE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PRURITUS; RASH; SIDE EFFECT; URTICARIA; VERTIGO;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 0032802427     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958010-00009     Document Type: Article

References (50)

1. 1. Nadler LM. The malignant lymphomas. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill Inc., 1991: 1599-612
2. 2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 Sep 1; 84 (5): 1361-92
3. 3. Rosenberg SA, Berard CW, Brown BW, et al. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35
4. 4. Fisher RI, Oken MM. Clinical practice guidelines: non-Hodgkin's lymphomas. Cleve Clin J Med 1995; 62 Suppl. 1: 6-42
5. 5. Horning SJ, Rosenberg SA. The natural history of initially untreated low grade non-Hodgkin's lymphomas. N Engl J Med 1984 Dec 6; 311: 1471-5
6. 6. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993 Oct; 20 Suppl. 5: 75-88
7. 7. Urba WJ, Longo DL. Lymphocytic lymphomas: clinical course and management. In: Moossa AR, Schimpff SC, Robson MC, editors. Comprehensive textbook of oncology, 2nd ed. v. 2. Baltimore: Williams and Wilkins, 1991: 1277-95
8. 8. Longo DL. Immunotherapy for non-Hodgkin's lymphoma. Curr Opin Oncol 1996; 8: 353-9
9. 9. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 Jan 15; 83 (2): 435-45
10. 10. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12 (3): 177-86
11. 11. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994 Oct 15; 84: 2457-66
12. 12. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-33
13. 13. Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981 Jan; 67: 134-40
14. 14. Mathas S, Kommert K, Dörken B, et al. Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation [abstract]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 405a
15. 15. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 Aug; 16: 2825-33
16. 16. Czuczman M, Grillo-López AJ, White CA, et al. Rituxan/ CHOP chemoimmunotherapy in patients with low-grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) [abstract]. J Immunother 1997; 20: 401
17. 17. Gianni AM, Magni M, Di Nicola M, et al. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with rituximab and high-dose chemotherapy [abstract no. 481]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 119a
18. 18. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997 Oct; 15: 3266-74
19. 19. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 Sep 15; 90: 2188-95
20. 20. Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994 Jun 15; 83 (12): 3800-7
21. 21. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993 Jun 15; 81 (12): 3449-57
22. 22. Gupta RK, Summers KE, Lister TA. PCK analysis for the t(14;18) translocation in patients with recurrent follicular lymphoma following immunotherapy with rituximab (IDEC-C2B8) [abstract no. 974]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 239a
23. 23. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001
24. 24. Piro L, White CA, Grillo-Lopez AJ, et al. Rituxan™(rituximab, IDEC-C2B8): interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma [abstract no. 2272]. Blood 1997 Nov 15; 90 Suppl. 1, Part 1: 510a
25. 25. Davis T, Levy R, White CA, et al. Rituximab: phase II (PII) retreatment (RcRx) study in patients (pts) with low-grade or follicular (LG/F) NHL [abstract no. 1710]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 414a
26. 26. Foran JM, Rohatiner AZS, Cunningham D, et al. Immunotherapy of recurrent follicular lymphoma (FL) with rituximab (IDEC-C2B8): preliminary results of an ongoing UK multicentre trial [abstract no. P-0969]. Br J Haematol 1998 Jul; 102 (1): 243
27. 27. Foran JM, Rohatiner AZS, Cunningham D, et al. Immunotherapy of mantle cell lymphoma (MCL), lymphoplasmacytoid lymphoma (LPC) and Waldenstrom's macroglobulinemia (WM), and small lymphocytic lymphoma (SLL) with rituximab (IDEC-C2B8): preliminary results of an ongoing international multicentre trial [abstract no O-0586]. Br J Haematol 1998 Jul; 102 (1): 149
28. 28. Piro L, White CA, Grillo-López AJ, et al. Rituximab in patients (pts) with relapsed low-grade or follicular non-Hodgkin's lymphoma (LG/F NHL): response rate and duration with a weekly times 8 dosing regimen [abstract no. 49]. Proc Am Soc Clin Oncol 1999; 18: 14a
29. 29. Janakiraman N, McLaughlin P, White CA, et al. Rituximab: correlation between effector cells and clinical activity in NHL [abstract no. 1384]. Blood 1998 Nov 15; 92 Suppl. I, Pt 1: 337a
30. 30. McLaughlin P, Grillo-Lopez AJ, Maloney DG, et al. Efficacy controls and long term follow-up of patients (pts) treated with rituximab for relapsed or refractory, low-grade or follicular (R-LB/F) NHL [abstract no. 1712]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1; 414a
31. 31. Maloney DG, Davis T, Levy R. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. Reply [letter]. J Clin Oncol 1998 Apr; 16: 1636-7
32. 32. Kinoshita T, Nagai H, Murate T, et al. CD20-negative relapse in B-cell lymphoma after treatment with rituximab [letter]. J Clin Oncol 1998 Dec; 16 (12): 3916
33. 33. Davis T, Levy R, White CA, et al. Retreatments with RITUXAN (rituximab, Idec-C2B8) have significant efficacy, do not cause hama, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL) [abstract no. 2269]. Blood 1997 Nov 15; 90 Suppl. I, Part 1: 509
34. 34. Hainsworth JD, Burris H, Scullin DC, et al. Rituximab induction and maintenance therapy in patients (pts) with previously untreated low-grade non-Hodgkin's lymphoma (NHL): preliminary results of Minnie Pear Cancer Research Network phase II trial [abstract no. 105]. Proc Am Soc Clin Oncol 1999; 18: 29
35. 35. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999 Jan; 17 (1): 268-76
36. 36. Czuczman M, Grillo-Lopez AJ, White CA, et al. Rituximab/ CHOP chemoimmunotherapy in patients (pts) with low grade lymphoma (LG/F NHL): progression free survival (FPS) after three years (median) follow up. 1999, Roche Pharmaceuticals, data on file
37. 37. Davis T, Maloney D, White CA, et al. Combination immunotherapy of low grade or follicular non-Hodgkins lymphoma with rituximab and alpha interferon: interim analysis [abstract no. 39]. Proc Am Soc Clin Oncol 1998 May; 17: 11a
38. 38. Coiffier B. Rituximab in diffuse large B cell and mantle cell lymphomas [abstract no. 020]. Ann Oncol 1998; 9 Suppl. 3: 27
39. 39. Tsai DE, Moore HCF, Porter DL, et al. Progressive intermediate grade non-Hodgkin's lymphoma after high dose therapy and autologous peripheral stem cell transplantation (PSCT) has a high response rate to rituximab [abstract no. 1713]. Blood 1998 Nov 15; 92 Suppl. I, Part 1: 415a
40. 40. Fisher RI. Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 1996; 7 Suppl. 6: S35-9
41. 41. Byrd JC, White CA, Link B, et al. Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: preliminary evidence of activity [abstract no. 433]. Blood 1998 Nov 15; 92 Suppl. I, Pt I: 106a
42. 42. Link BK, Grossbard ML, Fisher RI, et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL [abstract no. 7]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 3a
43. 43. NewsEdge Corporation. Roche's rituximab European warnings strengthened following eight cases of severe cytokine release syndrome; Idec/Genentech discussing Rituxan labeling revisions with FDA. Health News Daily (online), 1 Dec 1998. Media release, downloaded 3 Dec 1998
44. 44. Janeway CA, Travers P. Immunobiology: the immune system in health and disease. London: Current Biology Ltd, 1994
45. 45. IDEC Pharmaceuticals Corporation, Genentech Inc. Rituxan (rituximab) prescribing information. Revised 1998 Sep
46. 46. Anonymous. Fatal ADRs with Roche's MabThera. Scrip 1998 Dec 4; 2393: 17
47. 47. Hoffmann-La Roche AG. MABTHERA (Rituximab) prescribing information. Revised 27 Nov 1998
48. 48. Byrd JC, Waselenko JK, Maneatis TA, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid tumor lysis [abstract no. 432]. Blood 1998 Nov 15; 92 Suppl. 1, Part 1: 106a
49. 49. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999 Mar; 17 (3): 791-5
50. 50. Winkler U, Jensen M, Manzke O, et al. Severe side effects in patients with B-cell chromic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab [abstract no. 4228]. Blood 1998 Nov 15; 92 Suppl. 1, Part 2: 285b